Retatrutide 10mg (GLP-3 R)
Triple GIP/GLP-1/Glucagon agonist — the next generation of metabolic weight loss peptides.
14.9%
Avg body weight reduction
68wk
STEP-1 trial duration
FDA
Reviewed mechanism
Retatrutide is a triple GIP/GLP-1/Glucagon receptor agonist that showed 24.2% average weight loss in Phase 2 trials — potentially the most powerful anti-obesity peptide ever studied.
24.2% Weight Loss
Phase 2 NEJM publication — the largest weight reduction percentage ever published for any anti-obesity agent.
Triple Agonist
GIP + GLP-1 + Glucagon — three distinct metabolic pathways activated simultaneously.
Phase 3 Active
Currently in Phase 3 clinical trials — the most closely watched compound in anti-obesity medicine.
Retatrutide (GLP-3 R) 10mg: The Triple Agonist Protocol
Mechanism · Evidence · Application
Retatrutide is a "triple agonist" — a single molecule that simultaneously activates three distinct metabolic hormone receptors: GIP (Glucose-Dependent Insulinotropic Polypeptide), GLP-1 (Glucagon-Like Peptide-1), and the Glucagon receptor. This triple mechanism distinguishes it from semaglutide (single GLP-1 agonist) and tirzepatide (dual GIP/GLP-1 agonist) and has produced the most dramatic weight loss data in the history of pharmaceutical anti-obesity medicine.
The Third Receptor: Glucagon
The addition of glucagon receptor agonism is the key differentiator. Glucagon promotes lipolysis (fat breakdown), increases energy expenditure, and drives hepatic fat reduction more aggressively than GLP-1 or GIP alone. However, pure glucagon agonism raises concerns about hyperglycemia. Retatrutide's design balances glucagon-mediated fat burning with GIP and GLP-1's insulin-stimulating effects, creating a metabolic equilibrium that drives fat loss without dangerous glucose elevation.
Phase 2 Clinical Data
The Phase 2 trial published in the New England Journal of Medicine (2023) showed: - 24.2% average body weight reduction at 48 weeks (12mg dose) - 17.5% weight reduction at the 4mg dose - Significant improvements in triglycerides, blood pressure, and waist circumference - Safety profile comparable to other GLP-1 class agents
Research Status
Retatrutide (LY3437943) is currently in Phase 3 trials. The Phase 2 data has made it one of the most watched compounds in metabolic medicine.
Metabolic & Weight Loss Results
24.2% average weight loss in Phase 2 — potentially the highest ever recorded
Triple GIP/GLP-1/Glucagon activation: three independent fat-loss mechanisms
Glucagon receptor agonism drives hepatic fat reduction and energy expenditure
Significantly reduces triglycerides, blood pressure, and visceral fat
Currently in Phase 3 trials — the most advanced triple agonist in development
NEJM Phase 2 publication — high-quality peer-reviewed evidence base
Weight Loss Protocol Guide
Retatrutide 10mg (GLP-3 R) Protocol Guide
Phase 2 Escalation Protocol (Research Reference):
· Weeks 1–4: 2mg once weekly
· Weeks 5–8: 4mg once weekly
· Weeks 9–12: 8mg once weekly
· Weeks 13+: 12mg once weekly (Phase 2 maximum)
Injection:
· Once-weekly subcutaneous injection
· Standard GLP class dose escalation to manage gastrointestinal effects
· Same injection sites as tirzepatide (abdomen, thigh, upper arm)
Retatrutide 10mg (GLP-3 R)
Apollo Peptides Sciences
$149.99
Buy from ApolloAffiliate link · supports PeptidesClav
Body Composition
Triple GIP/GLP-1/Glucagon agonist — the next generation of metabolic weight loss peptides.
Quality Assurance
HPLC Testing
Purity verified per batch
Mass Spectrometry
Molecular identity confirmed
Certificate of Analysis
Publicly available
US-Based Supplier
Apollo Peptides Sciences
Synergistic Combinations
Stack Retatrutide 10mg (GLP-3 R) With
Ready to Start?
Begin your Retatrutide 10mg (GLP-3 R) protocol
Source from Apollo Peptides Sciences — HPLC-tested, mass-spectrometry verified, with a Certificate of Analysis per batch.
Shop Retatrutide 10mg (GLP-3 R) at Apollo